JessicaKaplanAltmanMD

Oncology • Chicago, IL

Hematologic Oncology

Professor in Medicine-Hematology/Oncology, Northwestern University Medical School

Join to view full profile

Dr. Altman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Altman's full profile

Already have an account?

Office
675 N Saint Clair St
Fl 14
Chicago, IL 60611
Phone+1 312-695-0990

Fax+1 312-695-7814
Is this information wrong?

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
University of ChicagoResidency, Internal Medicine, 2001 - 2004
University of Pittsburgh School of MedicineClass of 2001

Certifications & Licensure

IL State Medical License 2001 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 12
Active, not recruiting
Phase 2
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients Start of enrollment: 2007 Dec 01
Completed
Phase 2
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Start of enrollment: 2004 Sep 21
Completed
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos Start of enrollment: 2011 Jan 01
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia Start of enrollment: 2011 Jun 01
Withdrawn
Phase 1
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy Start of enrollment: 2011 Jul 01
Completed
Phase 2
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Start of enrollment: 2012 Mar 01
Terminated
Phase 3
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission Start of enrollment: 2012 Jul 01
Completed
Phase 1
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Start of enrollment: 2012 Sep 01
Completed
Phase 1
BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia Start of enrollment: 2012 Oct 01
Active, not recruiting
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients Start of enrollment: 2013 Apr 01
Completed
Phase 2
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Start of enrollment: 2015 Mar 11
Terminated
Phase 1
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
Completed
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2018 Nov 14
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2023 Jul 11
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eig...
Yasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, Rory M Shallis, Andrew H Matthews, Talha Badar, Emily M Geramita, Vamsi K Kota, Alok Swaroop, Peter Doukas, D...> ;American Journal of Hematology. 2024 Apr 1
Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.
Santana-Santos, L., Alvey, E., Xia, Z., Sukhanova, M., Gao, J., Fu, L., Chen, Q., Wolniak, K., Aqil, B., Behdad, A., Ji, P., Abaza, Y., Altman, J., Chen, Y., Lu, X.> ;European Journal of Haematology. 2024 Feb 22
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Altman, J., Zuckerman, T., Koprivnikar, J., McCloskey, J., Kota, V., Keng, M., Frankfurt, O., Abaza, Y., Bixby, D., Emadi, A., Burch, M., Bhatnagar, B., Luger, S., Per...> ;Blood Advances. 2023 Dec 26
Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemia.
Richard M Stone, Mikkael A Sekeres, Altman, J.> ;Blood Advances. 2023 Dec 26
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or ...
Jan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Caroline E Roe, Jonathan M Irish, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan ...> ;Annals of Hematology. 2024 Jan 1
2 citations
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
Fabio Efficace, Francesco Cottone, Betina Yanez, Vamsi Kota, Fausto Castagnetti, Giovanni Caocci, Massimiliano Bonifacio, Andrea Patriarca, Isabella Capodanno, Maria C...> ;Cancer. 2024 Jan 1
3 citations
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
Shallis, R., Daver, N., Altman, J., Komrokji, R., Pollyea, D., Badar, T., Bewersdorf, J., Bhatt, V., de Botton, S., de la Fuente Burguera, A., Carraway, H., Desai, P.,...> ;The Lancet. Haematology. 2023 Sep 1
2 citations
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
Keith W Pratz, Mohamad Cherry, Jessica K Altman, Brenda W Cooper, Nikolai A Podoltsev, Jose Carlos Cruz, Tara L Lin, Gary J Schiller, Joseph G Jurcic, Adam Asch, Ruish...> ;Journal of Clinical Oncology. 2023 Sep 10
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.
Harry J Iland, Nigel Russell, Richard Dillon, Andre C Schuh, Aditya Tedjaseputra, Andrew Wei, Asim Khwaja, Steven Knapper, Steven W Lane, John Reynolds, Mary Frances M...> ;Blood Advances. 2023 Jun 13
17 citations
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
Guillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, Jessica K Altman, Amir T Fathi, Olatoyosi Odenike, Gail J Roboz, Kendra Sweet, Crystal Miller, Anders Wennborg...> ;The Lancet. Haematology. 2023 Apr 1
8 citations
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.
Shivani Handa, Jeong-Ok Lee, Andriy Derkach, Richard M Stone, Alan Saven, Jessica K Altman, Michael R Grever, Kanti R Rai, Madhulika Shukla, Shreya Vemuri, Skye Montoy...> ;Blood. 2022 Dec 22
8 citations
TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
Rory M Shallis, Naval G Daver, Jessica K Altman, Robert P Hasserjian, Hagop M Kantarjian, Uwe Platzbecker, Valeria Santini, Andrew H Wei, David A Sallman, Amer M Zeidan> ;Cancer. 2023 Jan 15
45 citations
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Eunice S Wang, Pau Montesinos, Mark D Minden, Je-Hwan Lee, Michael Heuser, Tomoki Naoe, Wen-Chien Chou, Kamel Laribi, Jordi Esteve, Jessica K Altman, Violaine Havelang...> ;Blood. 2022 Oct 27
Non-leukemic presentation of acute promyelocytic leukemia as a testicular mass with associated non-canonicalmutation.
Barina Aqil, Juehua Gao, Heidi R Rahn, Madina Sukhanova, Xinyan Lu, Jessica Altman, Lawrence Jennings, Qing Chen, Yi-Hua Chen> ;Leukemia & Lymphoma. 2022 Dec 1
5 citations
Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia.
Yang Mei, Kehan Ren, Yijie Liu, Annabel Ma, Zongjun Xia, Xu Han, Ermin Li, Hamza Tariq, Haiyan Bao, Xinshu Xie, Cheng Zou, Dingxiao Zhang, Zhaofeng Li, Lili Dong, Amit...> ;The Journal of Clinical Investigation. 2022 Sep 1
1 citations
Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients.
Taylor Zak, Juehua Gao, Amir Behdad, Jayesh Mehta, Jessica K Altman, Peng Ji, Xinyan Lu, Madina Sukhanova> ;Leukemia & Lymphoma. 2022 Dec 1
1 citations
Advances in the pharmacological management of acute myeloid leukemia in adults.
Yazan Numan, Yasmin Abaza, Jessica K Altman, Leonidas C Platanias> ;Expert Opinion on Pharmacotherapy. 2022 Sep 1
49 citations
Venetoclax Plus Gilteritinib for-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Naval Daver, Alexander E Perl, Joseph Maly, Mark Levis, Ellen Ritchie, Mark Litzow, James McCloskey, Catherine C Smith, Gary Schiller, Terrence Bradley, Ramon V Tiu, K...> ;Journal of Clinical Oncology. 2022 Dec 10
7 citations
Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype.
Hamza Tariq, Liron Barnea Slonim, Zachary Coty Fattal, Mir B Alikhan, Jeremy Segal, Sandeep Gurbuxani, Irene B Helenowski, Hui Zhang, Madina Sukhanova, Xinyan Lu, Jess...> ;British Journal of Haematology. 2022 Jun 1
19 citations
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Alexander E Perl, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Nicki Panoskaltsis, Christian Recher, Catherine C Smith, Mark J Levis, Stephen ...> ;Blood Cancer Journal. 2022 May 30
2 citations
Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan Area.
Alain Mina, Carlos Galvez, Reem Karmali, Mary Mulcahy, Xinlei Mi, Masha Kocherginsky, Michael J Gurley, Neelima Katam, William Gradishar, Jessica K Altman, Michael G I...> ;Cancers. 2022 Apr 28
31 citations
Structural racism is a mediator of disparities in acute myeloid leukemia outcomes.
Abraham, I., Rauscher, G., Patel, A., Pearse, W., Rajakumar, P., Burkart, M., Aleem, A., Dave, A., Bharadwaj, S., Paydary, K., Acevedo-Mendez, M., Goparaju, K., Gomez,...> ;Blood. 2022 Apr 7
5 citations
Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, ...
Juehua Gao, Sandeep Gurbuxani, Taylor Zak, Masha Kocherginsky, Peng Ji, Firas Wehbe, Qing Chen, Yi Hua Chen, Xinyan Lu, Lawrence J. Jennings, Olga Frankfurt, Jessica K...> ;Genes, Chromosomes & Cancer. 2021 Oct 28
Interferon maintenance for prevention of relapse in favorable risk AML
Sara Small, Jessica K. Altman, Leonidas C. Platanias> ;Leukemia & Lymphoma. 2021 Sep 3
4 citations
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)
Hagop M. Kantarjian, Kebede H. Begna, Jessica K. Altman, Stuart L. Goldberg, Mikkael A. Sekeres, Stephen A. Strickland, Martha Arellano, David F. Claxton, Maria R. Bae...> ;Cancer. 2021 Aug 23
Join now to see all

Journal Articles

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine

Lectures

Targeting Treatment According to Molecular Assessment of Acute Myeloid Leukemia
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Clinical Outcomes of Venetoclax Therapy in Patients with Relapsed/Refractory (r/r) Non Hodgkin Lymphomas (NHL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
MDS + AML MATTER: A Multidisciplinary Approach to Testing and Diagnosis, Evaluation of Risk, and Personalized Treatment Selection
60th American Society of Hematology Annual Meeting - 12/1/2018
Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Highlights of ASH® San Diego, CA
American Society of Hematology (ASH), San Diego, California - 1/18/2013
Join now to see all

Press Mentions

Improving Treatment for Hairy Cell LeukemiaJanuary 11th, 2023
Study Shows Structural Racism Can Result in Poorer Leukemia OutcomesMarch 7th, 2022
Expect More Health Plans, Insurers, and Stable Premiums in 2022 as Part of Affordable Care ActAugust 10th, 2021
Join now to see all